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Estonia—as new EU members and remaining EU countries as old members. 
METHODS: A systematic review of the following databases was conducted: Medline 
(PubMed), Embase, Cochrane. In addition, NICE, INAHTA, HTAI, and ISPOR Inter-
net pages were searched. The following key words were used: cost of illness diabetes 
with name of a country or burden of illness diabetes with name of a country. Studies’ 
design, methods, scope, and results were compared. Direct and indirect costs were 
considered separately, detailed costs’ categories and costs related to complications 
were distinguished. Perspectives, time frames were taken into consideration and 
current exchange rates for communication purposes were used. Studies published in 
English language were included. RESULTS: Only 12 studies concerning cost of dia-
betes type 1 and 2 and their complications in new EU countries were found as com-
pared to 67 from old EU members. On the side of new EU members, one study was 
found in Lithuania and Bulgaria, three in Czech Republic, and seven in Poland. In old 
EU countries, one study was found in Luxembourg and Greece, two in Austria, 
Belgium, Finland, and Ireland, three in France and The Netherlands, seven in Spain 
and Italy, eight in Great Britain, 13 in Sweden, and 16 in Germany. CONCLUSIONS: 
Results of this review revealed the necessity of carrying out more studies concerning 
cost of diabetes and its complications in new EU members.
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OBJECTIVES: Diabetic foot (DF) is one of the most important complications of 
diabetes mellitus. If not treated properly, diabetic foot may often lead to infections, 
amputations, and ﬁ nally to disability. Unfortunately, only few studies of the cost of 
diabetic foot treatment were available in Russia; most of the studies were completed 
about 10 years ago. We suggested that the data of earlier studies could not reﬂ ect 
present level of expenditures. Therefore, we launched a study of the cost of diabetic 
foot treatment in present conditions. METHODS: We have analyzed the data of 146 
inpatients treated in diabetic foot department at Scientiﬁ c Centre for Endocrinology 
(Moscow, Russia) in 2008–2009. The patients’ data were input into a specially 
designed medical information system. The patients were sorted into three main groups: 
1) diabetic polyneuropathy without diabetic foot (N = 37); 2) diabetic foot without 
amputations (N = 58); and 3) patients with amputations due to diabetic foot (N = 
51). To calculate the total cost of DF treatment, costs of diagnostic procedures, medi-
cines, bandaging, surgical operations, and staying in the hospital were summed. 
RESULTS: Mean cost of treatment of one DF patient was equal to 81,700 rubles 
(US$2645), which is about 30% higher than previously reported ﬁ gures. It is mainly 
due to larger introduction of recombinant insulins into routine treatment of diabetic 
patients. Mean cost of treatment of DF patients with amputations was signiﬁ cantly 
higher than in those without amputations, mostly due to additional costs of surgical 
treatment and longer stay in a hospital. Moreover, the mean cost of medicines for DF 
patients with amputations was almost twice higher than for DF patients without 
amputations. CONCLUSIONS: The cost of diabetic foot treatment in Russia increased 
approximately 30% during last 10 years. The results will be used to assess cost-
effectiveness of various drug treatments of diabetic foot.
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OBJECTIVES: Damage to the recurrent laryngeal nerve (RLN) is one of the principal 
reasons for malpractice claims against surgeons in otorhinolaryngology. Intraoperative 
neuromonitoring (IONM), facilitating the identiﬁ cation of RLN, has been demon-
strated to be a valid technical support to reduce intraoperative risks. Aim of this study 
was to evaluate the additional hospitalization costs for thyroidectomy due to IONM, 
against the mentioned clinical and administrative advantages. METHODS: The study 
was performed in an experienced Italian University Hospital, in which the learning 
curve for this technology is considered completed. Through a microcosting approach, 
the thyroidectomy patient care process (with and without IONM) was costed consider-
ing direct costs only (staff time, consumables, equipment, drugs, operating room, and 
general expenses) and according to the hospital perspective. Unit costs were collected 
from hospital accounting and standard tariff lists. a differential analysis was per-
formed to highlight additional resource consumption (time effort, consumables, tech-
nology equipment) due to IONM usage. To assess the impact of the technology on 
hospital management, three scenarios were considered: 1) traditional thyroidectomy; 
2) thyroidectomy with IONM in a high-volume setting (ﬁ ve procedures per week); 
and 3) thyroidectomy with IONM in a low-volume setting (one procedure per week). 
RESULTS: The cost for hospitalization for a traditional thyroidectomy was c3471. If 
IONM is used, costs increase as follows: +7% in a high-volume setting (c3713) and 
+9% in a low-volume setting (c3770). IONM therefore represents only the 6% to 7% 
of the total hospitalization costs. CONCLUSIONS: IONM for thyroid surgery could 
reduce the risk of RLN damages and of the consequent malpractice claims against a 
very low impact on hospital budget, accounting only for the 7% of the hospitalization 
costs for a thyroidectomy. Considering that IONM could be useful in all surgical 
procedures where nerves are at risk, the economic impact could be even lower due to 
a higher level of usage of the equipment.
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OBJECTIVES: The available T2DM (type 2 diabetes mellitus) therapies attend with 
weight gain, which affects for the disease outcomes in a very extent way. Weight gain 
could worsen the long-term effect of insulin therapy (increased risk of insulin resis-
tance, hypertension, dyslipidemia), which inﬂ uences the total treatment cost. Long-
acting insulin analogue therapies (insulin detemir and glargine) offer improved 
pharmacokinetic and pharmacodynamic properties compared to regular human 
insulin. In a previous meta-analysis, detemir caused signiﬁ cant lower weight gain than 
glargine (−2.04 kg after 6 months therapy). Our research aimed to determine the 
effects of weight gain and calculate the total treatment cost. METHODS: On the basis 
of a systematic literature review, we found many consequences, which could be obesity 
related. Because of its important effect and bride prevalence, we analyzed the CHD 
(coronary heart disease) risk changes related to the weight gain. We modiﬁ ed the 10 
years risk—calculated with the UKPDS risk engine—with the effects of the weight gain 
published in a meta-analysis. We aggregated the differences in natural outcomes 
(number of avoided fatal and nonfatal events) and in monetary unit, based on real-
world data. RESULTS: In our analysis, we assessed that insulin detemir-treated 
patients—due to the favorable features regarding weight gain compared to glargine—
experience smaller (cca 2%) CHD risks. It means, for the current treated Hungarian 
population, that there are 223 coronary (158 fatal of this) events avoidable in 10 years 
horizon using detemir insulin instead glargine. The estimated savings of social insur-
ance would be around 224 million HUF on the basis of a Hungarian burden of dia-
betes complication study. CONCLUSIONS: Obesity and weight gain-related aspects 
should be priorized as the main international tendencies showed. It is not only neces-
sary on the policy level, but also in “individual” level in the cost-effectiveness analysis 
as well.
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OBJECTIVES: To examine the association of HbA1c at diagnosis with cost and clini-
cal outcomes in patients with type 2 diabetes (T2D) using three different diabetes 
treatment strategies. METHODS: An existing Monte Carlo diabetes model was used 
to generate demographic and clinical characteristics for 10,000 random patients simu-
lated from the time of T2D diagnosis. Fixed initial HbA1c values were assigned (range: 
7–12%). Input distributions were derived from the literature, with diabetes complica-
tions occurring in: retinopathy, nephropathy, neuropathy, coronary heart disease, and 
stroke. The diabetes-related costs, percentage of patients reaching HbA1c target 
(<7%), complication events, and mortality over 10 years were evaluated using the 
following treatment strategies: (S1) addition of oral antihyperglycemic agents (OHAs) 
at 3-month intervals then starting insulin after 9 months; (S2) addition of OHAs at 
6-month intervals then starting insulin after 2 years; and (S3) addition of OHAs only. 
All treatment strategies began with metformin then sulphonylurea and/or thiazolidin-
edione were added if target was not reached. RESULTS: Diabetes-related costs 
increased as initial HbA1c increased for all three strategies. S1 had the greatest increase 
($5300–$7750) followed by S3 ($4200–$5250) per 1% HbA1c increase from 7% to 
10%. S2 had the smallest rate of increase ($3350–$4950). S3 was the least costly until 
HbA1c exceeded 10%; however, even at HbA1c of 8%, S3 had fewer patients ever 
reaching target (S3 = 79% vs. S1 and S2 = 95% [standard errors, SE < 0.41%]). For 
10,000 patients with initial HbA1c of 9%, the total counts of complications were: S1 
= 4360; S2 = 4126; S3 = 5009 (SE < 67) with mortality rates of 42.5%, 41.9%, and 
45.2% (SE < 0.56%), respectively. CONCLUSIONS: In this model, S2 had the lowest 
complication rates and mortality in patients with T2D. Starting HbA1c affected S1 
cost more than other strategies. Strategies with other treatments or alternative timing 
strategies can be speciﬁ ed and analyzed using this model.
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OBJECTIVES: Response to GH therapy in children with IGHD can be further opti-
mized. To evaluate the economic beneﬁ t of injecting GH with easypod®, an electronic 
autoinjector that objectively monitors drug administration, enabling differentiation of 
poor adherers from low responders. METHODS: A discrete event simulation model 
was developed to model continuous, intermittent (four injections/week) and discontin-
ued GH usage in children with IGHD until ﬁ nal height. a cohort of children (age: 4–12 
years, growth delay: −4.0– −2.5 standard deviation scores [SDS] at baseline) was 
modeled to initiate GH (0.03 mg/kg/day). Annual height gains of 1.2 to 0.8 SDS in year 
1 were assumed to be 30% and 60% lower in each subsequent year of continuous and 
intermittent use, respectively. Baseline nonadherence was 9.3 persons per 100 person-
